Scientists at McMaster University have discovered that the hormone GDF15, known for curbing appetite and aiding weight loss, also plays a critical role in protecting the liver from inflammation and scarring regardless of weight changes.
- GDF15 reduces liver inflammation even without weight loss
- Activates a brain-liver pathway releasing anti-inflammatory glucocorticoids
- Potential new target for advanced fatty liver disease therapy
What happened
Researchers at McMaster University investigated the hormone GDF15, previously known for appetite suppression and weight loss effects, to understand its role in liver health. Using mouse models that replicate human fatty liver disease, they discovered that GDF15 activates a previously unidentified signaling pathway connecting the brain and liver.
This pathway stimulates the release of glucocorticoids, steroid hormones that help regulate metabolism and immune responses, which in turn reduce liver inflammation and slow fibrosis development. Importantly, these protective effects happened independently of any changes in body weight, food intake, or liver fat content.
Why it feels good
The findings reveal that GDF15 does more than control appetite—it acts as a natural anti-inflammatory agent that helps the liver defend itself against chronic injury. This challenges the common assumption that liver improvements from GDF15 are solely due to weight loss and opens up new possibilities for addressing liver inflammation directly.
For the millions worldwide affected by metabolic dysfunction-associated steatohepatitis, a condition that can progress to liver failure or cancer, this discovery brings hope. Targeting this hormone’s liver-protective pathway could complement existing treatments focused on weight loss, addressing a critical medical need for those who still suffer liver inflammation despite improved weight metrics.
What to enjoy or watch next
Future investigations may explore therapies designed to enhance or mimic GDF15’s brain-to-liver anti-inflammatory pathway, offering new approaches to manage advanced fatty liver disease alongside weight management strategies. Early preclinical drug candidates related to this pathway are already under study, making this an exciting avenue for medical advancement.
Meanwhile, continued research on how GDF15 influences immune cell behavior in the liver could reveal broader implications for inflammatory and metabolic diseases. Staying tuned to developments from McMaster and collaborating research groups promises insight into novel treatments that harness the body’s innate systems for healing.